Category Archives: Safety

Desperate Measures: Industry Teams with Parallel Traders to Tackle Counterfeiters in Europe

While action is heating up at the international level to tackle counterfeit drugs, Europe is making its own efforts to stop fake medicines from entering the legal supply chain. An improbable cross-sector partnership is struggling to secure support for a pan-European system to keep counterfeits out. It’s improbable because it brings together not only manufacturers, […]
Also posted in Anti-counterfeiting, Europe, Global, Guest Blog, Regulatory | Tagged , , , , , , | Leave a comment

EMA to Review Safety of Ibuprofen Medicines

The European Medicine Agency’s Pharmacovigilance and Risk Assessment Committee (PRAC) has started a review to evaluate the cardiovascular risks with systemic ibuprofen medicines.
Also posted in Europe, Global, Regulatory | Tagged , , , , , | Leave a comment

Lilly Increases Access to Clinical Trials Data

Eli Lilly and Company has announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. The website, which houses data from several clinical trial sponsors, was created with support from PhRMA and EFPIA to increase access to and transparency of clinical trial results for researchers around the world.  
Also posted in E-Media, multimedia, R&D, Regulatory, Technology | Tagged , | Leave a comment

US Pharmacopeia Head Wants Fresh Outlook

In anticipation of the 200th anniversary of the United States Pharmacopeia (USP) in 2020, the organization’s new leadership is taking a fresh look at its role in setting standards for pharmaceutical development and production and how that has been altered by new regulatory policies and industry globalization. USP chief executive officer Ron Piervincenzi is consulting […]
Also posted in FDA, Regulatory | Tagged , , , | Leave a comment

Pfizer–AstraZeneca: Implications for the Future of International Pharma

By Peter O’ Donnell. The Pfizer-AstraZeneca courtship raises many fascinating questions about the future shape of the international pharmaceutical industry, but it is also revealing some remarkable displays of parochialism. Even the olympian Financial Times has been displaying some nationalistic sympathies that sit oddly with its customary laissez-faire liberalism. A recent editorial seemed to argue strongly for some form […]
Also posted in Deals, Europe, Global, Guest Blog, Op-Ed | Tagged , , | 2 Comments
  • Categories

  • Meta